(Total Views: 702)
Posted On: 03/06/2021 5:16:26 PM
Post# of 153967
Green On Monday???
Global News Article 3/5/21
Reuter's Article 3/5/21
Bloomberg Article 3/5/21
Associated Press Article 3/5/21
Rumored Fox News Broadcast 3/7/21
More media coverage? Undiscovered? & yet to be published this weekend?
Extreme demand/need, absolute best drug available for s/c, unmet med need
Janet W. FDA says "pandemic" de-emphasizing p values & stat sig emphasizes may be effective + safety
FDA has allowed present eIND and OLE to continue unchanged
FDA may have 42 day s/c data which should be compelling
FDA should have present s/c eIND data & present OLE data
FDA does have prior eIND data, 15% death rate s/c among 76 patients
Should be buying on Monday due to "Fear Of Missing Out"
Should be shorts buying to cover short positions on Monday
LL is 24% better on critical deaths vs an already approved FDA EUA s/c drug (remdesivir)
1200 patients 820 HIV, no adverse side effects = pristine safety
6 day reduction in hospital stays for critical patients (insurance firms will love that)
At day 28, 11% of critical SOC folks leave hospital cured/alive vs 28% with LL
Extension of s/c Trial appears to be “during pendency of ongoing regulatory discussions” implying it is support full FDA approval while EUA may come at any time.
% of severe who progressed to critical in SOC group, should be much higher than in LL group.
US FDA has competition: Brazil, Philipines, Canada, the UK, surely others
Global News Article 3/5/21
Reuter's Article 3/5/21
Bloomberg Article 3/5/21
Associated Press Article 3/5/21
Rumored Fox News Broadcast 3/7/21
More media coverage? Undiscovered? & yet to be published this weekend?
Extreme demand/need, absolute best drug available for s/c, unmet med need
Janet W. FDA says "pandemic" de-emphasizing p values & stat sig emphasizes may be effective + safety
FDA has allowed present eIND and OLE to continue unchanged
FDA may have 42 day s/c data which should be compelling
FDA should have present s/c eIND data & present OLE data
FDA does have prior eIND data, 15% death rate s/c among 76 patients
Should be buying on Monday due to "Fear Of Missing Out"
Should be shorts buying to cover short positions on Monday
LL is 24% better on critical deaths vs an already approved FDA EUA s/c drug (remdesivir)
1200 patients 820 HIV, no adverse side effects = pristine safety
6 day reduction in hospital stays for critical patients (insurance firms will love that)
At day 28, 11% of critical SOC folks leave hospital cured/alive vs 28% with LL
Extension of s/c Trial appears to be “during pendency of ongoing regulatory discussions” implying it is support full FDA approval while EUA may come at any time.
% of severe who progressed to critical in SOC group, should be much higher than in LL group.
US FDA has competition: Brazil, Philipines, Canada, the UK, surely others
(11)
(0)
